Switching to IPX203 from IPX066 Significantly Improves “Good On” Time and Reduces Motor Fluctuations Under Real-World Conditions
Objective: To evaluate the change in daily “Good On” time and motor fluctuations during conversion of patients from IPX066 to IPX203 as an interim analysis…Subcutaneous Levodopa Infusion in Multiple System Atrophy: a Case Series
Objective: To describe safety, tolerability and clinical response to continuous subcutaneous (SC) levodopa infusion in three patients with multiple system atrophy (MSA). Background: Response to…Tremor-onset Parkinson’s Disease: Does Leg Tremor Portend a Poor Prognosis?
Objective: This study aims to assess the prognosis of baseline leg tremor-onset in autopsy-verified Parkinson’s Disease (PD) patients. Background: PD is a chronic neurological condition with a multifactorial etiology composed…Personalised Selection Of Device-Aided Infusion Therapies In Advanced Parkinson’s Disease: A European Expert Delphi Consensus
Objective: To develop an expert consensus on personalised treatment selection in advanced Parkinson’s disease (aPD) patients who are considered suitable for transition to device-aided therapies…Use of Mucuna Pruriens (M. Pruriens) in People with Parkinson’s Disease (PwPD)
Objective: To characterize M. pruriens use among local (primarily Argentinian) PwPD. Background: M. pruriens is a leguminous plant used in Ayurvedic medicine to treat Parkinsonism…Evaluating the Conversion of Immediate-Release and/or Extended-Release Levodopa to IPX203 in Patients with Parkinson’s Disease
Objective: This quality improvement (QI) project was conducted to evaluate the impact of the conversion from immediate-release (IR) and/or extended-release (ER) levodopa (LD) to mucoadhesive polymer…Continuous subcutaneous levodopa infusion in advanced Parkinson’s disease: a descriptive real-world cohort study
Objective: To describe clinical characteristics, treatment indications, safety profile, and treatment persistence in patients with advanced PD treated with continuous subcutaneous levodopa infusion. Background: Continuous…Vitamin D Status and Levodopa Responsiveness in Parkinson Disease and Association With Gastrointestinal Symptoms
Objective: To evaluate the association between serum vitamin D levels and clinical responsiveness to levodopa in patients with Parkinson disease and to explore potential relationships…Levodopa-Carbidopa Intestinal Gel Infusion Therapy in Advanced Parkinson’s Disease: Extension Study of Long-term outcomes of Single Centre experience
Objective: evaluate the long-term outcomes of levodopa-carbidopa intestinal gel (LCIG) infusion in patients with advanced PD with motor fluctuation in one centre Background: Levodopa-carbidopa intestinal…Single centre experience with subcutaneous foslevodopa/foscarbidopa for GBA Parkinson’s disease
Objective: To describe the clinical outcomes of two patients with GBA Parkinson’s disease (GBA-PD) and severe motor fluctuations treated with subcutaneous foslevodopa/foscarbidopa (fld/fcd) infusion. Background:…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 70
- Next Page »